Back

Initial combination therapy with ambrisentan and tadalafil for pulmonary arterial hypertension: clinical effect and haemodynamic changes. A multicenter retrospective analysis.

27 August 2017 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Chronic thromboembolic pulmonary hypertension Chronic pulmonary hypertension ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Michele D'Alto

AORN Ospedali dei Colli - Monaldi Hospital, Naples (Italy)

18 More presentations in this session

Presentation thumbnail
Professor D. Merkus (Munich, DE)
Abstract Slides
Presentation thumbnail
Doctor I. Hernandez Gonzalez (Valladolid, ES)
Abstract
Presentation thumbnail
Doctor J. Ueda (Osaka, JP)
Abstract Slides
Presentation thumbnail
Doctor I. Hernandez Gonzalez (Valladolid, ES)
Abstract Slides
Presentation thumbnail
Doctor T. Inami (Tokyo, JP)
Abstract

Access the full session

Session thumbnail
Poster session 3 - Chronic thromboembolic pulmonary hypertension

The Event

Event poster

ESC Congress 2017

27 August 2017 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Identification of predictors of response to initial oral combination therapy in WHO-functional class II or III PAH patients: A post-hoc analysis of the AMBITION study
28 August 2020
thumbnail
Webinar
Pulmonary Hypertension: clues to improved diagnosis and management using the ESC 2015 guidelines
23 November 2016
thumbnail
Congress Presentation
Ambrisentan retains its pro-autophagic activity on human pulmonary artery endothelial cells exposed to hypoxia in an in vitro model mimicking diabetes
30 August 2025
thumbnail
Congress Presentation
Safety and efficacy of sildenafil in patients with advanced heart failure.
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources